The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.
Abstract
A consecutive group of 259 patients with inoperable adenocarcinoma of the lung (ACL) were observed to define risk groups for and frequency of brain metastases together with prognosis. All patients received chemotherapy in a three-armed randomized trial. Brain metastases were diagnosed in 25 patients before protocol entry and in 37 during treatment. Brain autopsy was performed in 87 patients and was positive in 38 (44%). Eleven of these (29%) were not diagnosed clinically. Patients younger than 60 years had a somewhat higher overall frequency of brain metastases than older patients. Patients with initial performance status above 60% and patients responding to chemotherapy had higher risk for developing brain metastasis during treatment than other patients, probably because of the increasing cumulated risk for this complication with prolonged survival. Median survival after onset of brain metastases was 73 days and survival was significantly shorter for these patients than for patients without this complication at days 0, 90, 180, and 365 after protocol entry. Thus, brain metastases is a frequent complication in ACL and the frequency increases with prolonged survival. Survival after development of brain metastases is short and it is questionable whether the inclusion of this subgroup of ACL patients into experimental cytostatic treatments is justified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Ruckdeschel, J. C., Finkelstein, D. M., Ettinger, D. S., Creech, R. H., Mason, B. A., Joss, R., & Vogl, S. E. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.14 · Cited by 338
Komaki, R. R., Cox, J. D., & Stark, R. (1983) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(83)90319-x · Cited by 80
Cited by
Schouten, L. J., Rutten, J., Huveneers, H. A. M., & Twijnstra, A. (2002) · Cancer · doi:10.1002/cncr.10541 · Cited by 1,590
Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J., Vortmeyer, A., Jilaveanu, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 993
Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 485
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
Specific organ metastases and survival in metastatic non-small-cell lung cancer
TAMURA, T., KURISHIMA, K., NAKAZAWA, K., KAGOHASHI, K., ISHIKAWA, H., SATOH, H., & HIZAWA, N. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.410 · Cited by 341
Metadata
- Authors
- Sørensen, J. B., Hansen, H. H., Hansen, M., & Dombernowsky, P.
- Venue
- Journal of Clinical Oncology
- Published
- 1988-09
- Volume
- 6
- Issue
- 9
- Pages
- 1474-1480
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1888498899
- Cited by
- 339
- References
- 5
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. https://app.cochat.ai/papers/10.1200/jco.1988.6.9.1474
- The paper
- Sørensen, J. B., Hansen, H. H., Hansen, M., & Dombernowsky, P. (1988). Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1988.6.9.1474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.